Send to

Choose Destination
J Dermatolog Treat. 2020 May;31(3):213-221. doi: 10.1080/09546634.2019.1592096. Epub 2019 May 1.

The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study.

Author information

Department of Dermatology, Western Infirmary, Glasgow, United Kingdom.
Department of Dermatology, Castle Hill Hospital, East Yorkshire, United Kingdom.
Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom.
Department of Dermatology, Cannock Chase Hospital, Cannock, United Kingdom.
Department of Dermatology, The Royal Free Hospital, London, United Kingdom.
Department of Dermatology, East Surrey Hospital, Redhill, United Kingdom.
Department of Dermatology, Royal Devon & Exeter Hospital, Exeter, United Kingdom.
AbbVie Limited, Maidenhead, United Kingdom.
Department of Dermatology, Barts Health NHS Trust (Whipps Cross and Royal London Hospitals), London, United Kingdom.


Psoriasis can adversely affect quality of life (QoL) and emotional well-being. In this UK prospective observational study we evaluated the 'real-world' impact of adalimumab on QoL and the physical/psychological effects of moderate-to-severe psoriasis. Hundred and forty-three biologic-naïve patients with moderate-to-severe psoriasis, receiving adalimumab in clinical practice, were included. Patients completed a series of questionnaires at baseline (adalimumab initiation), 4 and 16-weeks and 6-months post-adalimumab initiation during routine visits. The main outcome measure was the proportion of Dermatology Life Quality Index (DLQI) 'responders' at 16 weeks, defined as ≥5 point reduction from baseline or DLQI = 0.90% (95% CI = 80.8%-94.6%) of evaluable patients were DLQI responders at 16-weeks. There were significant improvements at 16 weeks in patient-reported measures of QoL, mental and physical well-being, cutaneous body image, anxiety, depression and psoriasis severity, which were maintained at 6-months. Adalimumab treatment was associated with improvements in patients' QoL and psychological functioning, which occurred contemporaneously with improvements in cutaneous disease.


Adalimumab; body image; psoriasis; quality of life

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center